FTC Letters On Ambien CR Agreements Are "Educational" And A "Warning" For Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FTC's rebukes Sanofi, Watson and Synthon for failing to report agreements related to generic challenges of the insomnia drug, but Bureau of Competition Director Feinstein notes that the Commission is not seeking to fine the firms.
You may also be interested in...
Brand-Generic "Pay-For-Delay" Settlements Jump 63% In FY 2010
As a proportion of total settlements reported to FTC, however, the ones involving compensation to the generic firm remained the same.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.